We mined Google’s acquisitions, investments, and partnerships to discern the company's strategic priorities in the biopharma space.
Google — the fourth-largest company in the world by market cap — is expanding beyond web and search and making moves in the pharmaceuticals space.
The tech giant has made 90+ investments in the sector over the last 2 years. These investments complement activity from Google’s existing pharma-focused ventures, Verily Life Sciences, Calico Life Sciences, and Isomorphic Labs. For example, Verily recently raised $1B to further its mission to enable precision health.
Google also continues to invest in companies that combine research, clinical, and non-clinical data to customize drugs and healthcare to each patient’s specific needs.
Using CB Insights data, we uncovered the 5 most important strategic priorities highlighted by Google’s recent biopharma acquisitions, investments, and partnerships. We then categorized companies by their business relationships with Google across these priorities:
- Drug R&D tech
- Gene therapy
- Genomics
- Reproductive health
- Supply chain
